SipNose specializes in innovative non-invasive direct nose-to-brain delivery systems for neurological disorders. Their flexible platform is suitable for clinical and home use with varying applications for pediatric, adult, and geriatric patients. The company holds a device master file with the FDA and its technology is protected through intellectual property rights. SipNose collaborates with global pharmaceutical and biopharmaceutical partners and pursues drug-device combination products, specifically targeting the 505(b)(2) approval pathway. The intranasal drug delivery platform improves efficacy, safety, and patient compliance.